Why cytokine release syndrome happen during elranatamab treatment?
Best insight from top research papers
Cytokine release syndrome (CRS) can occur during elranatamab treatment due to the activation of T cells and subsequent release of cytokines. CRS is a supraphysiologic response characterized by excessive cytokine release and systemic manifestations . Elranatamab is an immunotherapy agent that activates T cells, leading to the release of cytokines . This excessive cytokine release can result in a wide range of symptoms, including fever, hypotension, myelosuppression, acute kidney injury, and disseminated intravascular coagulation . The severity of CRS can vary, and in some cases, it can progress rapidly and become life-threatening . Prompt recognition and management of CRS are crucial to prevent complications. Monitoring for signs of CRS and considering cytokine-directed therapy, such as IL-6 receptor-directed therapy with tocilizumab, may be necessary in cases of severe CRS .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The provided paper does not mention elranatamab treatment. | |
1 Citations | The provided paper is about cemiplimab-induced cytokine-release syndrome, not elranatamab treatment. Therefore, there is no information in the paper about why cytokine release syndrome happens during elranatamab treatment. |
517 Citations | The provided paper does not mention elranatamab treatment. |
| The provided paper is about a case report of fatal cytokine-release syndrome in a patient receiving toripalimab, not elranatamab. Therefore, there is no information in the paper about why cytokine release syndrome happens during elranatamab treatment. | |
| The provided paper does not mention elranatamab treatment. |
Related Questions
How does the FDA's warning on adalimumab affected?5 answersThe FDA's warnings on adalimumab have highlighted various aspects of its safety and efficacy. Adalimumab, a TNF-α blocking agent, is associated with common side effects like injection site reactions and infections. Studies have shown that adalimumab may increase the risk of malignancies, including lymphoma and non-melanoma skin cancer, compared to control groups. Despite these concerns, adalimumab remains a valuable treatment option for various autoimmune conditions, with ongoing benefits demonstrated in long-term extension studies and patient registries. The FDA's scrutiny emphasizes the need for monitoring and balancing the drug's advantages against potential risks, especially in patients with comorbidities like hepatic or renal conditions. Overall, the FDA's warnings underscore the importance of careful consideration and monitoring when using adalimumab for inflammatory conditions.
What is the optimal timing for administering eculizumab to patients with hemolytic uremic syndrome?5 answersThe optimal timing for administering eculizumab to patients with hemolytic uremic syndrome (HUS) remains uncertain. One study suggests that early initiation of eculizumab in patients with secondary aHUS can lead to better renal recovery compared to those who do not receive complement blockade. Another study found that discontinuation of eculizumab in patients with aHUS can result in HUS recurrence, and prompt resumption of eculizumab after relapse is effective in most patients. A retrospective study involving pharmacist involvement in the eculizumab initiation process showed a reduction in time to therapy initiation, which may translate to clinical benefit. However, the optimal duration of eculizumab therapy is still unknown, with some reports suggesting that shorter durations might be effective. Overall, further research is needed to determine the optimal timing and duration of eculizumab therapy in patients with HUS.
What are the future directions for Cytokine release syndrome management?5 answersFuture directions for cytokine release syndrome (CRS) management include exploring novel approaches to target CRS and developing strategies for patients who are unresponsive to current therapies. One potential approach is the use of emerging therapies that target CRS through novel mechanisms, such as IL-1 and IL-6 inhibitors, which have shown promise in treating or preventing severe CRS. Additionally, there is a need for accurate monitoring and timely prediction of CRS severity, which can be achieved through machine learning algorithms that utilize common vital signs and questionnaires. Another direction is the investigation of immunotherapeutic approaches to overcome CRS associated with T cell activation, such as Chimeric Antigen Receptor (CAR) T cells and bispecific T cell engagers. Furthermore, there is a need for further clinical investigation to assess the efficacy of these emerging approaches and to develop guidelines for managing CRS in different clinical settings.
What are the most common side effects of Omalizumab?5 answersThe most common side effects of Omalizumab include acute interstitial nephritis (AIN), altered latency, amplitude, and velocity values of peripheral nerves, and transient hair loss. No serious side effects were reported in patients receiving Omalizumab for chronic urticaria. Additionally, Omalizumab did not cause peripheral neuropathy in patients with chronic urticaria. There is no evidence to suggest that Omalizumab causes impairment of blood glucose regulation in non-diabetic patients.
Can plasma therapy lead to cytokine storm?9 answers
Why do cytokine storms occur?8 answers